Roche receives CE mark for AI based Kidney Klinrisk Algorithm

Chronic kidney disease (CKD) affects more than 700 million people worldwide and is broadly recognized as a global public health challenge. With early diagnosis and appropriate treatment, it is possible to delay or prevent kidney function decline, and reduce cardiovascular risk and related healthcare costs.

"The launch of the AI-based Kidney Klinrisk Algorithm as part of our chronic kidney disease algorithm panel, represents a significant advancement in the fight against this often silent, progressive disease," said Matt Sause, CEO, Roche Diagnostics. "The panel is designed to support physicians to make more informed decisions and manage patients’ kidney function at every stage of the disease. Most importantly, this also includes the possibility to assess adults with diabetes and hypertension, who are at elevated risk for kidney function decline and not yet diagnosed with CKD."

As per the release, healthcare professionals now have easy access to a comprehensive risk assessment solution for managing CKD proactively in both diagnosed and undiagnosed adults at risk, including in the early, often asymptomatic stages of the disease. This AI-based solution combines multiple input factors from routine blood and urine tests and aligns recommendations with clinical guidelines.

The panel is available in Europe and the United Kingdom, with a later launch in the United States, the Middle East, and Asia.